Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02855476 · ClinicalTrials.gov registry record
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
A clinical trial of Huntington's Disease, sponsored by University College, London.
- Recruiting
- Registry status
- 2,500
- Enrollment target
- 20
- Study locations
NCT02855476 is a study of Huntington's Disease that is actively recruiting participants, run by University College, London. The registered enrollment target is 2,500 participants, below the 4,481-participant average among 8 other Huntington's Disease trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02855476, a study of Huntington's Disease, is actively recruiting participants, sponsored by University College, London.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.
Conditions Studied
Study Locations (20)
Other
- Centre Hospitalier Universitaire d'Angers - Angers
- Le Centre Hospitalier Universitaire de Bordeaux - Bordeaux
- St Josef And Elisabeth Hospital - Bochum
- University Hospital of Erlangen - Erlangen
- George Huntington Institute - Münster
- Kbo-Isar-Amper-Klinikum Taufkirchen (Vils) - Taufkirchen
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta - Milan
- Lega Italiana Ricera Huntington - Rome
Ontario
- The Ottawa Hospital - Ottawa
- North York General Hospital - Toronto
- Centre for Movement Disorders - Toronto
Colorado
- Cenexel - Englewood
District of Columbia
- Georgetown University - Washington D.C.
Maryland
- John Hopkins University - Baltimore
North Carolina
- Wake Forest University - Winston-Salem
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- University of Texas Health Science Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2017-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02855476
The ClinicalTrials.gov registry entry for NCT02855476 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,481-participant average among 8 other Huntington's Disease trials with a reported enrollment target (44% lower). The listed sponsor is University College, London, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02855476 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Ontario, Colorado.
Frequently Asked Questions
What is clinical trial NCT02855476 about?
NCT02855476 is a clinical study titled "HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease". HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to...
What is the current status of trial NCT02855476?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2017-01-01.
What conditions does trial NCT02855476 study?
This clinical trial studies the following conditions: Huntington's Disease.
Who is sponsoring clinical trial NCT02855476?
This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02855476 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Maryland, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
RECRUITING
-
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
RECRUITING
-
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
COMPLETED · Phase 1
-
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
COMPLETED · Phase 2
-
FuRST 2.0 Cognitive Pre-Testing
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.